Compare Humana Inc (HUM) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Infosys Limited — how do they compare? Humana Inc trades at $434.98 (market cap $46.49B), while Infosys Limited trades at $10.76 (market cap $41.74B). The key difference: Humana Inc and Infosys Limited are close in size by market cap, and Infosys Limited pays the higher dividend (4.89%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Infosys Limited for 27 Days on average.
| HUM | INFY | |
|---|---|---|
Market Cap | $46.49B | $41.74B |
Volume | 2,567,704 | 31,354,285 |
Sector | Health | Technology |
52-Week High | $409.85 | $20.22 |
52-Week Low | $163.67 | $10.49 |
Typical Hold Time | 53 Days | 27 Days |
Enterprise Value | $53.84B | $39.48B |
Dividend Yield | 0.91% | 4.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
INFY trades at $10.78, up 2.18% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025 with a net income margin of 16.37%, and recent earnings show mixed results with a beat in Q1 2026 but a miss in Q2 2026. Positive news includes strategic AI collaborations with Columbia University and ABN Amro, highlighting growth initiatives in technology services.
The outlook is cautiously optimistic with a consensus price target of $11.48, offering potential upside. Risks include competitive pressures in IT services and volatile cash flow trends, with net cash flow turning negative in 2026. Analyst sentiment is mixed, with 35% buy ratings, but institutional activity shows increased holdings, supporting a stable foundation for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
